CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COGNITION THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.73−0.00 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $65.92M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
23.8%
23M of 95M shares
Institutional holders
66
4 new, 13 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $32.49K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aaron G.L. Fletcher | 6,059,555 | 6.90% | 13D (active) amendment | Sep 19, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 6,000,000 | 6.31% | $6.90M | – | 16.56% |
| DAVENPORT & Co LLC | 4,259,511 | 4.48% | $4.90M | +1,366,703 | 0.02% |
| Vanguard Capital Management LLC | 3,438,775 | 3.62% | $3.95M | +436,988 | 0.00% |
| BlackRock, Inc. | 1,261,993 | 1.33% | $1.45M | +293,631 | 0.00% |
| Chescapmanager LLC | 997,029 | 1.05% | $1.15M | – | 0.10% |
| Geode Capital Management, LLC | 910,006 | 0.96% | $1.05M | −10,202 | 0.00% |
| Renaissance Technologies LLC | 693,288 | 0.73% | $797.28K | −423,848 | 0.00% |
| Hilton Capital Management, LLC | 548,950 | 0.58% | $631.29K | – | 0.04% |
| Vanguard Fiduciary Trust Co | 508,220 | 0.53% | $584.45K | +44,536 | 0.00% |
| CM Management, LLC | 450,000 | 0.47% | $517.50K | +50,000 | 0.34% |
| Dauntless Investment Group, LLC | 371,701 | 0.39% | $427.46K | −59,299 | 0.34% |
| Sigma Planning Corp | 362,265 | 0.38% | $416.61K | +24,500 | 0.01% |
| State Street Corp | 348,983 | 0.37% | $401.33K | +34,500 | 0.00% |
| Tocqueville Asset Management L.P. | 320,500 | 0.34% | $368.58K | +125,500 | 0.00% |
| UBS Group AG | 218,536 | 0.23% | $251.32K | +141,663 | 0.00% |
| American Financial Group Inc | 205,000 | 0.22% | $235.75K | – | 0.08% |
| Northern Trust Corp | 178,202 | 0.19% | $204.93K | +9,516 | 0.00% |
| Voss Capital, LLC | 175,000 | 0.18% | $201.25K | −25,000 | 0.01% |
| Texas Capital Bank Wealth Management Services Inc | 143,296 | 0.15% | $164.79K | +20,000 | 0.01% |
| Charles Schwab Investment Management Inc | 84,940 | 0.09% | $97.68K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 23M | 23.8% | 4 / 23 | 10 / 13 | 3M | 1M |
| Q1 2026 | 75 | 21M | 22.5% | 13 / 18 | 14 / 14 | 5M | 1M |
| Q4 2025 | 78 | 21M | 22.6% | 17 / 17 | 16 / 8 | 3M | 3M |
| Q3 2025 | 69 | 21M | 22.4% | 31 / 23 | 4 / 8 | 12M | 1M |
| Q2 2025 | 48 | 11M | 11.8% | 7 / 10 | 7 / 10 | 1M | 1M |
| Q1 2025 | 51 | 12M | 12.2% | 11 / 10 | 12 / 4 | 1M | 1M |
| Q4 2024 | 45 | 11M | 11.7% | 8 / 12 | 9 / 2 | 7M | 0M |
| Q3 2024 | 40 | 4M | 4.5% | 10 / 6 | 5 / 14 | 1M | 2M |
| Q2 2024 | 46 | 5M | 5.6% | 5 / 14 | 8 / 6 | 1M | 2M |
| Q1 2024 | 47 | 7M | 7.5% | 15 / 9 | 10 / 5 | 3M | 3M |
| Q4 2023 | 37 | 7M | 7.5% | 7 / 10 | 2 / 4 | 3M | 0M |
| Q3 2023 | 36 | 7M | 7.6% | 2 / 5 | 7 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CGTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,444,295 | 2.57% | $2.81M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 871,598 | 0.92% | $1.00M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 416,139 | 0.44% | $491.04K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 275,235 | 0.29% | $316.52K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 143,771 | 0.15% | $169.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 118,702 | 0.12% | $140.07K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 84,940 | 0.09% | $75.56K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 51,054 | 0.05% | $60.24K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 38,785 | 0.04% | $44.60K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 31,797 | 0.03% | $36.57K | 0.00% | Jun 30, 2026 |
| Gabelli Global Mini Mites Fund | 30,000 | 0.03% | $34.50K | 0.13% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 18,396 | 0.02% | $21.16K | 0.01% | Jun 30, 2026 |
| iShares Neuroscience and Healthcare ETF | 4,543 | 0.00% | $4.04K | 0.07% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -27,700 | -0.03% | -$31.86K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lisa Ricciardi | CEO & President, Director | 1,754,702 | 1.85% | Apr 20, 2026 |
| John Brendan Doyle | Chief Financial Officer | 618,942 | 0.65% | May 4, 2026 |
| Anthony Caggiano | Chief Medical Officer | 874,906 | 0.92% | Apr 20, 2026 |
| Aaron G.L. Fletcher | Director, 10% owner | 6,056,229 | 6.37% | Jun 22, 2026 |
| Bios Equity Partners, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| Ellen B. Richstone | Director | 83,500 | 0.09% | Jun 22, 2026 |
| Brett P. Monia | Director | 73,500 | 0.08% | Jun 22, 2026 |
| BIOS Fund I, LP | Director, 10% owner | 5,505,905 | 5.79% | Jun 22, 2026 |
| Bios Equity Partners II, LP | Director, 10% owner | 6,014,500 | 6.32% | Jun 22, 2026 |
| BIOS Capital Management, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| BIOS Fund II, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| BIOS Fund I QP, LP | Director, 10% owner | 5,499,905 | 5.78% | Jun 22, 2026 |
| Jack A. Khattar | Director | 73,500 | 0.08% | Jun 22, 2026 |
| BIOS Advisors GP, LLC | Director, 10% owner | 6,048,500 | 6.36% | Jun 22, 2026 |
| BIOS Fund II QP, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| Peggy Wallace | Director | 111,461 | 0.12% | Jun 22, 2026 |
| BIOS Memory SPV I, LP | Director, 10% owner | 6,081,229 | 6.39% | Jun 22, 2026 |
| BP Directors, LP | Director, 10% owner | – | – | Jun 20, 2025 |
| BIOS Equity Partners III, LP | Director, 10% owner | – | – | Jun 20, 2025 |
| BIOS Fund III, LP | Director, 10% owner | 6,048,500 | 6.36% | Jun 20, 2025 |
| BIOS Fund III QP, LP | Director, 10% owner | 5,499,905 | 5.78% | Jun 20, 2025 |
| BIOS Fund III NT, LP | Director, 10% owner | 5,483,841 | 5.77% | Jun 20, 2025 |
| BIOS Memory SPV II, LP | Director, 10% owner | 5,505,905 | 5.79% | Jun 20, 2025 |
| Leslie W. Kreis | Director, 10% owner | 6,014,500 | 6.32% | Jun 20, 2025 |
| Cavu Advisors, LLC | Director, 10% owner | – | – | Jun 20, 2025 |
| Cavu Management, LP | Director, 10% owner | 5,412,841 | 5.69% | Jun 20, 2025 |
| BIOS Fund II NT, LP | Director, 10% owner | – | – | Jun 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ellen B. Richstone Director | Jun 17, 2026 | Award | +25,000 | – | – | 83,500 |
| Jack A. Khattar Director | Jun 17, 2026 | Award | +25,000 | – | – | 73,500 |
| Peggy Wallace Director | Jun 17, 2026 | Award | +25,000 | – | – | 111,461 |
| BIOS Memory SPV I, LP Director, 10% owner | Jun 17, 2026 | Award | +25,000 | – | – | 81,229 |
| Brett P. Monia Director | Jun 17, 2026 | Award | +25,000 | – | – | 73,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2026 | Tax withholding | −8,567 | $1.28 | $10.97K | 618,942 |
| John Brendan Doyle Chief Financial Officer | Apr 16, 2026 | Buy | +10,000 | $1.13 | $11.30K | 627,509 |
| Lisa Ricciardi CEO & President, Director | Apr 16, 2026 | Buy | +9,175 | $1.10 | $10.09K | 1,715,851 |
| Anthony Caggiano Chief Medical Officer | Apr 16, 2026 | Buy | +10,000 | $1.11 | $11.10K | 874,906 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2026 | Tax withholding | −5,850 | $1.12 | $6.55K | 1,706,676 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2026 | Tax withholding | −4,680 | $1.12 | $5.24K | 864,906 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2026 | Tax withholding | −1,560 | $1.12 | $1.75K | 617,509 |
| Anthony Caggiano Chief Medical Officer | Feb 4, 2026 | Tax withholding | −26,919 | $1.03 | $27.73K | 869,586 |
| John Brendan Doyle Chief Financial Officer | Feb 4, 2026 | Tax withholding | −26,921 | $1.03 | $27.73K | 619,069 |
| Lisa Ricciardi CEO & President, Director | Feb 4, 2026 | Tax withholding | −51,704 | $1.03 | $53.26K | 1,712,526 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2026 | Award | +400,000 | – | – | 907,993 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2026 | Tax withholding | −11,488 | $1.12 | $12.87K | 896,505 |
| John Brendan Doyle Chief Financial Officer | Feb 3, 2026 | Award | +200,000 | – | – | 645,990 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2026 | Award | +800,000 | – | – | 1,790,266 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2026 | Tax withholding | −26,036 | $1.12 | $29.16K | 1,764,230 |
| John Brendan Doyle Chief Financial Officer | Dec 18, 2025 | Award | +30,000 | – | – | 455,350 |
| John Brendan Doyle Chief Financial Officer | Dec 18, 2025 | Tax withholding | −9,360 | $1.50 | $14.04K | 445,990 |
| Anthony Caggiano Chief Medical Officer | Dec 18, 2025 | Award | +65,000 | – | – | 528,273 |
| Anthony Caggiano Chief Medical Officer | Dec 18, 2025 | Tax withholding | −20,280 | $1.50 | $30.42K | 507,993 |
| Lisa Ricciardi CEO & President, Director | Dec 18, 2025 | Award | +75,000 | – | – | 1,013,666 |
| Lisa Ricciardi CEO & President, Director | Dec 18, 2025 | Tax withholding | −23,400 | $1.50 | $35.10K | 990,266 |
| Aaron G.L. Fletcher Director, 10% owner | Sep 19, 2025 | Option exercise | +7,729 | $0.84 | $6.49K | 56,229 |
| Lisa Ricciardi CEO & President, Director | Jul 29, 2025 | Tax withholding | −23,400 | $0.67 | $15.68K | 938,666 |
| Lisa Ricciardi CEO & President, Director | Jul 29, 2025 | Award | +75,000 | – | – | 962,066 |
| Anthony Caggiano Chief Medical Officer | Jul 29, 2025 | Award | +65,000 | – | – | 483,554 |
| Anthony Caggiano Chief Medical Officer | Jul 29, 2025 | Tax withholding | −20,281 | $0.67 | $13.59K | 463,273 |
| John Brendan Doyle Chief Financial Officer | Jul 29, 2025 | Tax withholding | −9,360 | $0.67 | $6.27K | 425,350 |
| John Brendan Doyle Chief Financial Officer | Jul 29, 2025 | Award | +30,000 | – | – | 434,710 |
| Brett P. Monia Director | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| Jack A. Khattar Director | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| Peggy Wallace Director | Jun 18, 2025 | Award | +34,000 | – | – | 86,461 |
| Ellen B. Richstone Director | Jun 18, 2025 | Award | +34,000 | – | – | 58,500 |
| BIOS Advisors GP, LLC Director, 10% owner | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| BIOS Fund III, LP Director, 10% owner | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2025 | Tax withholding | −9,692 | $0.45 | $4.36K | 404,710 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2025 | Tax withholding | −6,619 | $0.59 | $3.91K | 887,066 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2025 | Tax withholding | −5,296 | $0.59 | $3.12K | 418,554 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2025 | Tax withholding | −1,723 | $0.59 | $1.02K | 414,402 |
| John Brendan Doyle Chief Financial Officer | Feb 4, 2025 | Award | +295,000 | – | – | 416,125 |
| Anthony Caggiano Chief Medical Officer | Feb 4, 2025 | Award | +295,000 | – | – | 423,850 |
| Lisa Ricciardi CEO & President, Director | Feb 4, 2025 | Award | +631,300 | – | – | 893,685 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2025 | Tax withholding | −12,779 | $0.67 | $8.56K | 128,850 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2025 | Tax withholding | −28,960 | $0.67 | $19.40K | 262,385 |
| Lisa Ricciardi CEO & President, Director | Jan 31, 2025 | Buy | +38,851 | $0.77 | $29.92K | 38,851 |
| Ellen B. Richstone Director | Jun 7, 2024 | Award | +8,500 | – | – | 24,500 |
| Brett P. Monia Director | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Jack A. Khattar Director | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Peggy Wallace Director | Jun 7, 2024 | Award | +8,500 | – | – | 52,461 |
| Bios Equity Partners II, LP Director, 10% owner | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Leslie W. Kreis Director, 10% owner | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2024 | Tax withholding | −8,699 | $1.95 | $16.96K | 121,125 |
| Lisa Ricciardi CEO & President, Director | Mar 14, 2024 | Buy | +5,700 | $1.75 | $9.98K | 291,345 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2024 | Award | +75,000 | – | – | 285,645 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2024 | Award | +60,000 | – | – | 141,629 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2024 | Award | +20,000 | – | – | 129,824 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.